Tumor Microenvironment Targeting System for Glioma Treatment Via Fusion Cell Membrane Coating Nanotechnology.

Junning Ma,Lisi Dai,Jianbo Yu,Hui Cao,Youmei Bao,JiaJia Hu,Lihui Zhou,Jiqi Yang,Adame Sofia,Hongwei Chen,Fan Wu,Zhikai Xie,Wenqi Qian,Renya Zhan

DOI: https://doi.org/10.1016/j.biomaterials.2023.122026

IF: 14

2023-01-01

Biomaterials

Abstract:The tumor microenvironment (TME), comprising cancer cells and stroma, plays a significant role in determining clinical outcomes, which makes targeting cancer cells in the TME an important area of research. One way in which cancer cells in the TME can be specifically targeted is by coating drug-encapsulated nanoparticles (NPs) with homotypic cancer cell membranes. However, incomplete targeting is inevitable for biomimetic nanoformulations coated with only cancer cell membranes because of the inherent heterogeneity of the TME. After observing the structural connection between glioma-associated stromal cells (GASCs) and glioma cells from a clinic, we designed a novel drug delivery system that targets the TME by coating polylactic-co-glycolic acid (PLGA) NPs with GASC-glioma cell fusion cell (SG cell) membranes. The resulting SGNPs inherited membrane proteins from both the glioma membrane and GASC membrane, significantly enhancing the tumor targeting efficiency compared to nanoformulations coated with cancer cell membranes alone. We further demonstrated that encapsulation of temozolomide (TMZ) improved the therapeutic efficacy of TMZ in both heterotopic and orthotopic glioma mouse models. Owing to its significant efficacy, our TME-targeting nanoplatform has potential for clinical applications in the treatment of various cancers.